TY - JOUR
T1 - A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy
AU - Manoharan, Niranjan
AU - Subramanian, Prem Sagar
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.
AB - Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.
KW - Harvoni
KW - Ischemic optic neuropathy
KW - NAION
UR - http://www.scopus.com/inward/record.url?scp=85020750085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020750085&partnerID=8YFLogxK
U2 - 10.1016/j.ajoc.2017.03.002
DO - 10.1016/j.ajoc.2017.03.002
M3 - Article
C2 - 29260058
AN - SCOPUS:85020750085
SN - 2451-9936
VL - 6
SP - 55
EP - 57
JO - American Journal of Ophthalmology Case Reports
JF - American Journal of Ophthalmology Case Reports
ER -